These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808 [TBL] [Abstract][Full Text] [Related]
23. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Haraya K; Tachibana T; Nanami M; Ishigai M Xenobiotica; 2014 Dec; 44(12):1127-34. PubMed ID: 25030041 [TBL] [Abstract][Full Text] [Related]
24. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Proetzel G; Roopenian DC Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339 [TBL] [Abstract][Full Text] [Related]
25. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417 [TBL] [Abstract][Full Text] [Related]
26. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504 [TBL] [Abstract][Full Text] [Related]
27. Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance. Goulet DR; Watson MJ; Tam SH; Zwolak A; Chiu ML; Atkins WM; Nath A Drug Metab Dispos; 2018 Dec; 46(12):1900-1907. PubMed ID: 30232177 [TBL] [Abstract][Full Text] [Related]
28. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors. Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857 [TBL] [Abstract][Full Text] [Related]
29. Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics. Bajardi-Taccioli A; Blum A; Xu C; Sosic Z; Bergelson S; Feschenko M Mol Immunol; 2015 Oct; 67(2 Pt B):616-24. PubMed ID: 26254986 [TBL] [Abstract][Full Text] [Related]
30. The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals. Baldwin WM; Valujskikh A; Fairchild RL Am J Transplant; 2019 Jul; 19(7):1881-1887. PubMed ID: 30903736 [TBL] [Abstract][Full Text] [Related]
31. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM MAbs; 2016; 8(4):775-86. PubMed ID: 27030023 [TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies directed against human FcRn and their applications. Christianson GJ; Sun VZ; Akilesh S; Pesavento E; Proetzel G; Roopenian DC MAbs; 2012; 4(2):208-16. PubMed ID: 22453095 [TBL] [Abstract][Full Text] [Related]
34. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering. Wang Y; Tian Z; Thirumalai D; Zhang X J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896 [TBL] [Abstract][Full Text] [Related]
35. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A MAbs; 2015; 7(2):331-43. PubMed ID: 25658443 [TBL] [Abstract][Full Text] [Related]
36. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT MAbs; 2021; 13(1):1893888. PubMed ID: 33691596 [TBL] [Abstract][Full Text] [Related]
37. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. Borrok MJ; Wu Y; Beyaz N; Yu XQ; Oganesyan V; Dall'Acqua WF; Tsui P J Biol Chem; 2015 Feb; 290(7):4282-90. PubMed ID: 25538249 [TBL] [Abstract][Full Text] [Related]
38. Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells Qureshi OS; Sutton EJ; Bithell RF; West SM; Cutler RM; McCluskey G; Craggs G; Maroof A; Barnes NM; Humphreys DP; Rapecki S; Smith BJ; Shock A MAbs; 2024; 16(1):2300155. PubMed ID: 38241085 [TBL] [Abstract][Full Text] [Related]
39. Target-independent variable region mediated effects on antibody clearance can be FcRn independent. Kelly RL; Yu Y; Sun T; Caffry I; Lynaugh H; Brown M; Jain T; Xu Y; Wittrup KD MAbs; 2016 Oct; 8(7):1269-1275. PubMed ID: 27610650 [TBL] [Abstract][Full Text] [Related]
40. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]